A Study to Learn About the Effects and Safety of Marstacimab (PF-06741086) in Teenagers and Adults with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B With or Without Inhibitors

An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis